Please select the option that best describes you:
How would you approach metastatic NSCLC (adenocarcinoma without brain mets) with PD-L1 >50% and BRAF V600E driver mutation?
Answer from: Medical Oncologist at Academic Institution
I would start with dabrafenib + trametinib based on what we know from available relevant trials and the literature.
-- Response rate for dabrafenib + trametinib as 1st-line therapy for people with BRAF V600E NSCLC was 64%.
-- Response rate for pembrolizumab as 1st-line therapy for people with NSCL...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Agree with starting BRAF/MEKi first and IO at progression. Trials are looking at combining the two strategies.
Comments
Medical Oncologist at Kaiser Permanente
I have one patient with the exact situation. The P...
I have one patient with the exact situation. The P...